For the first time, cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity have been united under a single clinical framework. The 2026 AHA/ACC/ADA/ASN Guideline for Cardiovascular-Kidney-Metabolic Syndrome — the first-ever CKM guideline — was published in June 2026 in JACC and Circulation, and featured prominently in the August 11, 2026 JAMA issue.[1]
CKM syndrome recognizes something clinicians have known intuitively for years: these conditions do not occur in isolation. Obesity drives insulin resistance, which damages renal tubules, which accelerates glomerulosclerosis, which amplifies hypertension, which accelerates coronary atherosclerosis. Each disease amplifies the others. Managing them separately — one specialist per organ — misses the shared biology.
The guideline defines four CKM stages. Stage 0 is no risk factors present. Stage 1 is excess adiposity or metabolic syndrome without diabetes or CKD. Stage 2 is metabolic risk factors with CKD (eGFR <60 or significant albuminuria) or type 2 diabetes. Stage 3 is very high-risk CKD, severely elevated albuminuria, or high cardiovascular risk with diabetes. Stage 4 is established cardiovascular disease with underlying CKM risk factors.[1]
The staging system is designed to be actionable, not just descriptive. Each stage carries specific pharmacologic and lifestyle recommendations. GLP-1 receptor agonists and SGLT2 inhibitors are highlighted across multiple stages as interventions that simultaneously address cardiac, renal, and metabolic axes — making them the cornerstone drugs of CKM management.[1,2]
Clinical Context
The guideline explicitly retires the 2013 AHA/ACC/TOS Obesity Guideline, expanding its scope from weight management to the full cardiorenal-metabolic continuum. The ADA, ACC, AHA, and ASN coming together for a single document marks an unusual level of multidisciplinary consensus — recognizing that the patient with heart failure, CKD stage 3a, and a BMI of 38 needs cardiorenal rather than organ-siloed care.
Your patient with T2D, CKD stage 3b (eGFR 42), and diastolic dysfunction likely qualifies for Stage 3 CKM. They need an SGLT2 inhibitor — which reduces worsening heart failure, slows CKD progression, and reduces cardiovascular death all at once. The guideline formalizes what has been building from EMPA-KIDNEY, DAPA-CKD, EMPEROR-Preserved, and CREDENCE: the three-way cardiorenal-metabolic benefit of these agents is now a guideline class I recommendation.
Limitations
The staging system is new and not yet validated in prospective cohorts. Some clinicians will find a 4-stage framework too simple for the heterogeneity within each stage. The guideline's treatment recommendations are largely extrapolated from single-disease trials; head-to-head CKM-specific trial data do not yet exist.
References
[1] Writing Committee. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome. J Am Coll Cardiol. 2026. PMID: 42263157. [PubMed]
[2] Wheeler DC, et al. Effects of Dapagliflozin on Major Adverse Kidney Events in Patients with Diabetic and Non-Diabetic Chronic Kidney Disease (DAPA-CKD). Lancet. 2021;396(10265):1838-1848. PMID: 33152323. [PubMed]